RecruitingNCT05848427

The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19

The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19.


Sponsor

Lebanese University

Enrollment

1,000 participants

Start Date

Mar 28, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

The coronavirus disease 2019 (COVID-19) has spread rapidly and caused a global pandemic, as defined by the WHO, within a short period of time. The prognostic of disease severity is still a challenge and early identification of risk factors to be involved in its progression is of high importance. The scoring of variables related to worse outcomes is key for a targeted and/or advanced protocol. Besides, the need for a predictive-wide model is mandatory for hospitalized unvaccinated patients to avoid any delay in the characterization of severe illness and the development of complications. The LUSZ COVID-19 Severity Index was developed as a predictive tool based on \>100 risk factors/biomarkers, that could effectively identify high-risk patients and prevent mortality.


Eligibility

Exclusion Criteria1

  • \-

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLUSZ P

LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.


Locations(2)

Lebanese University

Tripoli, North Lebanon, Lebanon

SZUMC

Zghartā, North Lebanon, Lebanon

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05848427


Related Trials